Immunotherapy Drugs: Global Markets

Table of Contents

Chapter 1 Introduction

Study Goals and Objectives
Scope of Report
Methodology

• Market Estimates

Information Sources

• Primary Research
• Secondary Research

Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

Immunotherapy
Towards Combination Immunotherapy
Focusing on Cell-mediated Adaptive Immunity
Fine Tuning Vs. Boosting Cancer Immunity
Early Vs. Advanced Stage Cancer Immunotherapy
Personalized Treatment Paradigm
Clinically Significant Types of Cancers

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Stomach Cancer
• Leukemia

Future of Immunotherapy in Cancer
Infectious Diseases
Immunotherapy against Autoimmune Disorders
Immunotherapies against Infectious Diseases
Biologics as Autoimmune Disorder Therapies
Trends in Autoimmune Disorder Therapies
Types of Immunotherapies

• Checkpoint Inhibitors
• Unmet Medical Needs
• New Biomarkers to Stratify Patients
• Relapse/Refractory Patients
• Treatment Efficacy and Tolerability
• Innovative Strategies
• Novel Targeted Approaches
• Monoclonal Antibodies
• Interleukins
• Interferons

Chapter 4 Market Dynamics

Strengths of Immunotherapy Market

• Growing Aging Population
• Rising Incidence of Diseases
• Patent Expirations
• Growing Pipeline
• Drive to Reduce Costs
• Government Incentives
• Collaborations and Partnerships
• Mergers and Acquisitions

Weaknesses of the Immunotherapy Market

• Manufacturing Process
• Process Definition and Testing and Validation
• Lack of Skilled Personnel
• Regulatory Guidelines
• Patent Litigation

Threats to Immunotherapy Market

• Unpredictable Regulatory Landscape
• Prescriptions by Medical Practitioners/Pharmacies
• Competition

Opportunities in the Immunotherapy Market

• Emerging Markets
• Technological Innovation and Improved Process Knowledge
• Pricing

Chapter 5 Impact of COVID-19 on the Pharmaceutical Industry

Short-term Impact
Change in Demand
Shift of Communication and Promotions to Remote Interactions
Changes to R&D
Long-term Impact
Delayed Approvals for Non-COVID-related Pharmaceutical Products
Self-sufficiency in the Pharmaceutical Industry
Changes in Consumption Trends in Health-related Products

Chapter 6 Market Breakdown by Product Type

Overview
Monoclonal Antibodies

• Market Overview
• Market Revenue
• Market Share

Market by Region

• Market Overview
• Market Revenue
• Market Share

Checkpoint Inhibitors

• Pembrolizumab
• Companion Diagnostic
• Clinical Trial Program
• Forecast for Pembrolizumab

Nivolumab (Opdivo)

• Companion Diagnostic
• Clinical Trial Program
• Forecast for Nivolumab

Atezolizumab (Tecentriq)

• Companion Diagnostic
• Clinical Trial Program
• Forecast for Atezolizumab

Avelumab (Bavencio)

• Companion Diagnostic
• Clinical Trial Program
• Forecast for Avelumab

Durvalumab (Imfinzi)

• Companion Diagnostic
• Clinical Trial Program
• Durvalumab Forecasts
• Yervoy (Ipilimumab)

Market by Region

• Market Revenue
• Market Share

Interferons and Interleukins

• Market Revenue

Market by Region
Market by Disease Area

Chapter 7 Market Breakdown by Region

Market Overview and Discussion
North America

• United States
• Canada

Europe
Asia-Pacific

• China
• Japan

Rest of the World

Chapter 8 Company Profiles

ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BAYER AG
BRISTOL MYERS SQUIBB
F. HOFFMANN-LA ROCHE LTD.
JOHNSON & JOHNSON
VIATRIS INC. (FORMERLY MYLAN)
NOVARTIS AG
PFIZER INC.
VERTEX PHARMACEUTICALS INC.

List of Tables

Summary Table B : Global Market for Immunotherapy Drugs, by Region, Through 2025
Summary Table A : Global Market for Immunotherapy Drugs, by Product Type, Through 2025
Table 1 : Stages of Lung Cancer
Table 2 : Biologics as Autoimmune Disorder Therapies
Table 3 : Adverse Events Associated with Immune-Checkpoint Blockade
Table 4 : Evolution of Monoclonal Antibodies
Table 5 : Advantages and Disadvantages of Monoclonal Antibodies
Table 6 : Murine Monoclonal Antibodies
Table 7 : Chimeric Monoclonal Antibodies
Table 8 : Humanized Monoclonal Antibodies
Table 9 : Human Monoclonal Antibodies
Table 10 : Selected Approved Interferon Alpha Analogs
Table 11 : Global Market for Immunotherapy Drugs, by Product Type, Through 2025
Table 12 : Global Market for Monoclonal Antibodies, by Type, Through 2025
Table 13 : Global Market Shares for Monoclonal Antibody Drugs, by Type, 2019
Table 14 : Global Market for Monoclonal Antibody Drugs, by Region, Through 2025
Table 15 : Global Market Shares for Monoclonal Antibody Drugs, by Region, 2019
Table 16 : Global Market for Checkpoint Inhibitors, 2019-2025
Table 17 : Pembrolizumab Approved Indications
Table 18 : Nivolumab Approved Indications
Table 19 : Atezolizumab Approved Indications
Table 20 : Avelumab Approved Indications
Table 21 : Durvalumab Approved Indications
Table 22 : Global Market of Checkpoint Inhibitors, by Region, Through 2025
Table 23 : Global Market Shares for Checkpoint Inhibitors, by Region, 2019
Table 24 : Global Market for Interferons and Interleukins, Through 2025
Table 25 : Global Market for Interferons and Interleukins, by Region, Through 2025
Table 26 : Global Market for Immunotherapy, by Therapeutic Area, Through 2025
Table 27 : Global Market for Immunotherapy Drugs, by Region, Through 2025
Table 28 : North American Market for Immunotherapy Drugs, by Country, Through 2025
Table 29 : North American Market for Immunotherapy Drugs, by Product Type, Through 2025
Table 30 : European Market for Immunotherapy Drugs, by Country, Through 2025
Table 31 : European Market for Immunotherapy Drugs, by Product Type, Through 2025
Table 32 : Asia-Pacific Market for Immunotherapy Drugs, by Country, Through 2025
Table 33 : Asia-Pacific Market for Immunotherapy Drugs, by Product Type, Through 2025
Table 34 : Chinese Market Statistics
Table 35 : Japanese Market Statistics
Table 36 : AbbVie: Product Portfolio
Table 37 : Amgen: Product Portfolio
Table 38 : AstraZeneca: Product Portfolio
Table 39 : Bayer AG: Product Portfolio
Table 40 : Johnson & Johnson: Product Portfolio
Table 41 : Viatris: Product Portfolio
Table 42 : Novartis AG: Product Portfolio
Table 43 : Pfizer: Product Portfolio
Table 44 : Pfizer: Pipeline Product Portfolio

List of Figures

Summary Figure A : Global Market for Immunotherapy Drugs, by Product Type, 2019-2025
Summary Figure B : Global Market for Immunotherapy Drugs, by Region, 2019-2025
Figure 1 : Annual Incidence and Mortality Data for Lung Cancer in the U.S., 1990-2020
Figure 2 : Annual Incidence and Mortality Data for Lung Cancer in Five EU Countries, 1975-2020
Figure 3 : Annual Incidence and Mortality Data for Lung Cancer in the Rest of the World, 1975-2020
Figure 4 : Five-Year Survival Rates, by Lung Cancer Stage
Figure 5 : Annual Incidence and Mortality Data for Breast Cancer in the U.S., 1975-2020
Figure 6 : Annual Incidence and Mortality Data for Breast Cancer in Five E.U. Countries., 1975-2020
Figure 7 : Annual Incidence and Mortality Data for Breast Cancer in Japan, 1975-2020
Figure 8 : Annual Incidence and Mortality Data for Breast Cancer in the Rest of the World, 1975-2020
Figure 9 : Five-Year Survival Rates, by Breast Cancer Stage
Figure 10 : Annual Incidence and Mortality Data for Colorectal Cancer in the U.S., 1975-2020
Figure 11 : Annual Incidence and Mortality Data for Colorectal Cancer in Five EU Countries, 1975-2020
Figure 12 : Annual Incidence and Mortality Data for Colorectal Cancer in Japan, 1975-2020
Figure 13 : Annual Incidence and Mortality Data for Colorectal Cancer in the Rest of the World, 1975-2020
Figure 14 : Five-Year Survival Rates, by Colorectal Cancer Stage
Figure 15 : Annual Incidence and Mortality Data for Stomach Cancer in the U.S., 1975-2020
Figure 16 : Annual Incidence and Mortality Data for Stomach Cancer in Five EU Countries, 1975-2012
Figure 17 : Annual Incidence and Mortality Data for Stomach Cancer in Japan, 1975-2020
Figure 18 : Annual Incidence and Mortality Data for Stomach Cancer in the Rest of the World, 1975-2020
Figure 19 : Five-Year Survival Rates, by Stomach Cancer Stage
Figure 20 : Annual Incidence and Mortality Data for Leukemia in the U.S., 1975-2020
Figure 21 : Annual Incidence and Mortality Data for Leukemia in Five EU Countries, 1975-2020
Figure 22 : Annual Incidence and Mortality Data for Leukemia in Japan, 1975-2020
Figure 23 : Annual Incidence and Mortality Data for Leukemia in the Rest of the World, 1975-2020
Figure 24 : Potential Targets for Checkpoint Inhibition in Clinical Evaluation
Figure 25 : SWOT Analysis of Immunotherapy Market
Figure 26 : Impact of COVID-19 on the Pharmaceutical Industry
Figure 27 : Global Market for Immunotherapy Drugs, 2019-2025
Figure 28 : Global Market Shares for Immunotherapy Drugs, by Product Type, 2019
Figure 29 : Global Market Shares for Monoclonal Antibody Drugs, by Type, 2019
Figure 30 : Global Market for Monoclonal Antibody Drugs, by Region, 2019-2025
Figure 31 : Global Market Shares for Monoclonal Antibody Drugs, by Region, 2019
Figure 32 : Pembrolizumab Comprehensive Clinical Trial Programs, by Status
Figure 33 : Pembrolizumab Comprehensive Clinical Trial Programs, by Therapy
Figure 34 : Pembrolizumab Comprehensive Clinical Trial Programs, by Cancer Type
Figure 35 : Global Market for Pembrolizumab, 2019-2025
Figure 36 : Nivolumab Comprehensive Clinical Trial Programs, by Status
Figure 37 : Nivolumab Comprehensive Clinical Trial Programs, by Therapy
Figure 38 : Nivolumab Comprehensive Clinical Trial Programs, by Cancer Type
Figure 39 : Global Market for Nivolumab, 2019-2025
Figure 40 : Atezolizumab Comprehensive Clinical Trial Programs, by Status
Figure 41 : Atezolizumab Comprehensive Clinical Trial Programs, by Therapy
Figure 42 : Atezolizumab Comprehensive Clinical Trial Programs, by Cancer Type
Figure 43 : Global Market for Atezolizumab, 2019-2025
Figure 44 : Avelumab Comprehensive Clinical Trial Programs, by Status
Figure 45 : Avelumab Comprehensive Clinical Trial Programs, by Therapy
Figure 46 : Avelumab Comprehensive Clinical Trial Programs, by Cancer Type
Figure 47 : Global Market for Avelumab, 2019-2025
Figure 48 : Durvalumab Comprehensive Clinical Trial Programs, by Status
Figure 49 : Durvalumab Comprehensive Clinical Trial Programs, by Therapy
Figure 50 : Durvalumab Comprehensive Clinical Trial Programs, by Cancer Type
Figure 51 : Global Market for Durvalumab, 2019-2025
Figure 52 : Global Market for Ipilimumab, 2019-2025
Figure 53 : Global Market for Checkpoint Inhibitors, by Region, 2019-2025
Figure 54 : Global Market Shares for Checkpoint Inhibitors, by Region, 2019
Figure 55 : Global Market for Interferons and Interleukins, by Region, 2019-2025
Figure 56 : Global Market Shares for Immunotherapy Drugs, by Region, 2019
Figure 57 : North American Market Shares for Immunotherapy Drugs, by Product Type, 2019
Figure 58 : European Market for Immunotherapy Drugs, by Country, 2019-2025
Figure 59 : European Market for Immunotherapy Drugs, by Product Type, 2019-2025
Figure 60 : Asia-Pacific Market Shares for Immunotherapy Drugs, by Product Type, 2019
Figure 61 : AbbVie Inc.: Annual Revenue, 2016-2019
Figure 62 : AbbVie: Revenue Share, by Region/Country, 2019
Figure 63 : AbbVie: Revenue Share, by Business Unit, 2019
Figure 64 : Amgen: Annual Revenue, 2016-2019
Figure 65 : Amgen: Revenue Share, by Region/Country, 2019
Figure 66 : Amgen: Revenue Share, by Products, 2019
Figure 67 : AstraZeneca: Annual Revenue, 2016-2019
Figure 68 : AstraZeneca: Revenue Share, by Region/Country, 2019
Figure 69 : AstraZeneca: Revenue Share, by Business Unit, 2019
Figure 70 : Bayer AG: Annual Revenue, 2016-2019
Figure 71 : Bayer AG: Revenue Share, by Region, 2019
Figure 72 : Bayer AG: Revenue Share, by Business Unit, 2019
Figure 73 : Bristol Myers Squibb: Annual Revenue, 2016-2019
Figure 74 : Bristol Myers Squibb: Revenue Share, by Region/Country, 2019
Figure 75 : Bristol Myers Squibb: Revenue Share, by Brands, 2019
Figure 76 : Hoffmann-La Roche: Annual Revenue, 2016-2019
Figure 77 : Hoffmann-La Roche: Revenue Share in Pharmaceutical Segment, by Region/Country, 2019
Figure 78 : Hoffmann-La Roche: Revenue Share, by Business Segment, 2019
Figure 79 : Johnson & Johnson: Annual Revenue, 2016-2019
Figure 80 : Johnson & Johnson: Revenue Share, by Region/Country, 2019
Figure 81 : Johnson & Johnson: Revenue Share, by Business Unit, 2019
Figure 82 : Viatris: Annual Revenue, 2016-2019
Figure 83 : Viatris: Revenue Share, by Region, 2019
Figure 84 : Viatris: Revenue Share, by Business Unit, 2019
Figure 85 : Novartis AG: Annual Revenue, 2015-2019
Figure 86 : Novartis AG: Revenue Share, by Region/Country, 2019
Figure 87 : Novartis AG: Revenue Share, by Business Segment, 2019
Figure 88 : Pfizer: Annual Revenue, 2016-2019
Figure 89 : Pfizer: Revenue Share, by Region/Country, 2019
Figure 90 : Pfizer: Revenue Share, by Business Segment, 2019
Figure 91 : Vertex Pharmaceuticals: Annual Revenue, 2016-2019
Figure 92 : Vertex Pharmaceuticals: R&D Expense Annual Revenue, 2017-2019
Figure 93 : Vertex Pharmaceuticals: Revenue Share, by Business Segment, 2019

当レポートのプレスリリースは発行されておりません。